Table 3 Analysis of glucocorticoid receptor genotypes and longitudinal trends for FEV1 and FVC
| Â | Â | Total population | F508del/F508del patients | ||||
|---|---|---|---|---|---|---|---|
|  | Genotype | Y6 (± SD) | k (± SD) | p | Y6 (± SD) | k (± SD) | p |
FEV 1 | |||||||
TthIII | CC | 95.5 (± 2.9) | -2.5 (± 0.5) | 0.7 | 89.2 (± 4.1) | -2.2 (± 0.7) | 0.4 |
|  | CT | 96.2 (± 4.1) | -2.9 (± 0.7) |  | 98.7 (± 5.4) | -3.8 (± 0.9) |  |
|  | TT | 88.8 (± 6.7) | -1.6 (± 1.1) |  | 94.4 (± 8.4) | -2.2 (± 1.3) |  |
ER22/23EK | GG | 95.2 (± 11.2) | -2.6 (± 1.7) | 0.4 | 94.6 (± 21.4) | -3.0 (± 2.9) | 0.7 |
|  | AA + AG | 92.6 (± 11.0) | -0.5 (± 1.7) |  | 90.4 (± 21.2) | -0.9 (± 2.8) |  |
N363S | AA | 95.5 (± 7.3) | -2.6 (± 1.4) | 0.5 | 95.3 ± (9.9) | -3.0 (± 2.2) | 0.5 |
|  | GG + AG | 89.9 (± 7.0) | -2.9 (± 1.4) |  | 85.3 ± (9.6) | -3.0 (± 2.2) |  |
BclI | CC | 96.4 (± 2.8) | -2.3 (± 0.5) | 0.02* | 92.0 (± 3.7) | -2.3 (± 0.6) | 0.01* |
|  | CG | 90.7 (± 3.9) | -2.8 (± 0.7) |  | 89.3 (± 5.2) | -3.1 (± 0.8) |  |
|  | GG | 106.8 (± 6.4) | -3.4 (± 1.2) |  | 111.0 (± 7.2) | -4.3 (± 1.3) |  |
FVC | |||||||
TthIII | CC | 97.6 (± 2.6) | -2.3 (± 0.4) | 0.8 | 92.1 (± 3.7) | -1.8 (± 0.6) | 0.9 |
|  | CT | 93.8 (± 3.5) | -1.7 (± 0.6) |  | 95.2 (± 5.0) | -2.2 (± 0.8) |  |
|  | TT | 92.3 (± 5.9) | -1.6 (± 0.9) |  | 92.8 (± 7.8) | -1.8 (± 1.3) |  |
ER22/23EK | GG | 95.6 (± 9.7) | -2.1 (± 1.4) | 0.1 | 93.8 (± 19.4) | -2.2 (± 2.7) | 0.5 |
|  | AA + AG | 86.4 (± 9.5) | +1.0 (± 1.4) |  | 89.4 (± 19.3) | 0.6 (± 2.6) |  |
N363S | AA | 95.2 (± 6.3) | -1.9 (± 1.2) | 0.9 | 94.1 (± 8.9) | -2.1 (± 2.0) | 0.8 |
|  | GG + AG | 94.9 (± 6.1) | -2.2 (± 1.2) |  | 88.4 (± 8.6) | -1.7 (± 2.0) |  |
BclI | CC | 96.0 (± 2.5) | -1.5 (± 0.4) | 0.04* | 91.7 (± 3.3) | -1.3 (± 0.4) | 0.02* |
|  | CG | 92.0 (± 3.5) | -2.1 (± 0.6) |  | 89.3 (± 4.7) | -2.1 (± 0.8) |  |
|  | GG | 104.0 (± 5.7) | -2.8 (± 0.1) |  | 107.8 (± 6.6) | -3.6 (± 1.2) |  |